Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. (2019)

• Record Type: Journal Article
• Authors: Nauffal, Mary; Werner, Lillian; Ni, Jian; Stone, Richard M.; DeAngelo, Daniel J.; McDonnell, Anne M.
• Is Part Of: Leukemia research reports. Volume 12(2019)
• Publication Date: 2019
• Subjects: Acute promyelocytic leukemia (APL) -- All-trans retinoic acid (ATRA) -- Differentiation syndrome; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2019.100189
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: All-trans-retinoic acid (ATRA) is the standard of care for the management of acute promyelocytic leukemia (APL), but can be associated with differentiation syndrome (DS). Over a seven-year period, we sought to determine the impact of ATRA initiation time on the development of DS. ATRA administration time had no impact on DS occurrence ( p = =0.13), APL risk ( p = =0.28) or regimen received ( p = =0.1). Patients with higher mean body mass index (BMI) were more likely to develop moderate or severe DS ( p = =0.02). Early treatment of APL is essential and maybe strongly considered in patients with elevated BMI.